Skip to content

Study · Animal study (in vivo) · rat · 2009

3 results

NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.

Bickerdike MJ, Thomas GB, Batchelor DC, Sirimanne ES, Leong W, Lin H, Sieg F, Wen J, Brimble MA, Harris PW, Gluckman PD

Journal of the neurological sciences20 Jan 2009Cited by 46 (Europe PMC)

PMID19157421 (opens in a new tab)DOI10.1016/j.jns.2008.12.003 (opens in a new tab)PepBankPUB-19157421
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with focal stroke, intravenous NNZ-2566 initiated 3 h after artery constriction significantly reduced infarct area on day 5.

    In plain wordsIn rats with focal stroke, intravenous NNZ-2566 reduced infarct area.

    Peptide
    Trofinetide
    Outcome
    DecreaseInfarct area on day 5
    Study

    ratn: not reported in source

    Acute focal stroke
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    3-10 mg/kg/h · intravenous infusion · 4 hAs given in this study (rat).

    Source sentences

    Summary
    An intravenous infusion of NNZ-2566 of 4 h duration (3-10 mg/kg/h), initiated 3 h after endothelin-induced middle-cerebral artery constriction, significantly reduced infarct area as assessed on day 5.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with MCAO, oral NNZ-2566 formulated as a microemulsion showed neuroprotective efficacy.

    In plain wordsIn rats with stroke, oral NNZ-2566 microemulsion showed neuroprotective effects.

    Peptide
    Trofinetide
    Outcome
    Not applicableOral neuroprotective efficacy
    Study

    ratn: not reported in source

    Acute focal stroke
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30-60 mg/kg · oralAs given in this study (rat).

    Source sentences

    Summary
    Neuroprotective efficacy in the MCAO model was also observed following oral administration of the drug (30-60 mg/kg), when formulated as a microemulsion.
    1 context sentence
    Summary · context
    In vivo, NNZ-2566 reduces injury size in rats subjected to focal stroke.
  3. 03LabIn vitro (cells)Mechanism

    In primary striatal cultures, NNZ-2566 significantly attenuated apoptotic cell death.

    In plain wordsIn cells from primary striatal cultures, NNZ-2566 reduced apoptotic cell death.

    Peptide
    Trofinetide
    Outcome
    DecreaseApoptotic cell death
    Study

    n: not reported in source

    Primary striatal cultures
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, NNZ-2566 significantly attenuates apoptotic cell death in primary striatal cultures, suggesting attenuation of apoptosis is one mechanism of action underlying its neuroprotective effects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.